Pro-inflammatory gene set (Chemokine (C-X-C motif) ligand 1, Chemokine (C-X-C motif) ligand 3, Interleukin-8, Chemokine (C-C motif) ligand 20, Interleukin-6, Interleukin-1 beta) (None)

The pro-inflammatory gene set consisting of CXCL1, CXCL3, CXCL8, CCL20, IL-6, and IL-1β represents a group of critical mediators in the human immune system that drive inflammation and leukocyte chemotaxis (UniProt P05231, P01584). These molecules are often co-regulated by the NF-κB signaling pathway and are elevated in response to pathogens or tissue damage (PubMed 31043481). CXCL1, CXCL3, and CXCL8 (IL-8) primarily function as chemoattractants for neutrophils via the CXCR1 and CXCR2 receptors, while CCL20 targets CCR6-expressing cells such as Th17 cells (PubMed 25108029, 10660613). IL-6 and IL-1β are pleiotropic cytokines that mediate systemic effects, including the induction of the acute-phase response and the modulation of T-cell differentiation. In clinical contexts, this gene set is associated with the pathogenesis of autoimmune diseases like rheumatoid arthritis and the progression of various cancers. Therapeutic strategies often involve targeting individual members of this set, such as using tocilizumab for IL-6 inhibition or canakinumab for IL-1β neutralization, to alleviate chronic inflammation and improve patient outcomes.

Other names

CXCL1, CXCL3, CXCL8, CCL20, IL-6, IL-1β – pro-inflammatory gene setInflammatory cytokine signatureNF-kappaB target gene setPro-inflammatory mediator cluster

Inhibition of pro-inflammatory signaling through the neutralization of specific cytokines (e.g., IL-6, IL-1β) or the blockade of their respective receptors (e.g., IL-6R, CXCR1/2), thereby reducing leukocyte recruitment and systemic inflammation.